Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SYRS Stock Forecast 2026-2027
$0.03
Current Price
$684,228
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to SYRS Price Targets
+79,900.0%
To High Target of $20.00
+21,900.0%
To Median Target of $5.50
+15,900.0%
To Low Target of $4.00
SYRS Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-62.5%
1 Year Change
0.0%
Year-to-Date Change
-99.6%
From 52W High of $6.93
+66.7%
From 52W Low of $0.02
📊 TOP ANALYST CALLS
Did SYRS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Syros is one of their latest high-conviction picks.
Latest SYRS Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, SYRS has a neutral consensus with a median price target of $5.50 (ranging from $4.00 to $20.00). The overall analyst rating is N/A (N/A/10). Currently trading at $0.03, the median forecast implies a 21,900.0% upside. This outlook is supported by 0 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward Tenthoff at Piper Sandler, projecting a 79,900.0% upside. Conversely, the most conservative target is provided by Jason Butler at JMP Securities, suggesting a 15,900.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SYRS Analyst Ratings
0
Buy
1
Hold
0
Sell
SYRS Price Target Range
Low
$4.00
Average
$5.50
High
$20.00
Current: $0.03
Latest SYRS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SYRS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2024 | JMP Securities | Jason Butler | Market Perform | Downgrade | $N/A |
| Nov 13, 2024 | HC Wainwright & Co. | Andrew Fein | Neutral | Downgrade | $1.00 |
| Nov 13, 2024 | TD Cowen | Phil Nadeau | Hold | Downgrade | $N/A |
| Nov 13, 2024 | Brookline Capital | Leah Rush | Hold | Downgrade | $N/A |
| Nov 1, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $6.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $6.00 |
| Aug 13, 2024 | JMP Securities | Jason Butler | Market Outperform | Maintains | $4.00 |
| Aug 13, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $5.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $15.00 |
| Jun 26, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $15.00 |
| May 15, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $15.00 |
| Apr 3, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $13.00 |
| Apr 1, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $15.00 |
| Oct 3, 2023 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $7.00 |
| Aug 9, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $15.00 |
| May 11, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $15.00 |
| May 11, 2023 | JMP Securities | Jason Butler | Market Outperform | Maintains | $15.00 |
| Mar 3, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $15.00 |
| Mar 3, 2023 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $13.00 |
| Jan 5, 2023 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $20.00 |
Syros Pharmaceuticals Inc. (SYRS) Competitors
The following stocks are similar to Syros based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Syros Pharmaceuticals Inc. (SYRS) Financial Data
Syros Pharmaceuticals Inc. has a market capitalization of $684,228 with a P/E ratio of 6.5x. The company generates $386,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -28,891.7% and return on equity of -777.0%.
Valuation Metrics
Market Cap
$684,228
Enterprise Value
$2.64M
P/E Ratio
6.5x
PEG Ratio
0.0x
Price/Sales
1.8x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-28,891.7%
Net Margin
0.0%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+8,688.0%
Current Ratio
2.3x
Debt/Equity
-5.4x
ROE
-777.0%
ROA
-59.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Syros Pharmaceuticals Inc. (SYRS) Business Model
About Syros Pharmaceuticals Inc.
What They Do
Develops gene-targeted therapeutics for diseases.
Business Model
Syros Pharmaceuticals utilizes its proprietary platform to discover and develop medicines by targeting gene regulatory regions. The company focuses on precision medicine, generating revenue through the advancement of innovative therapeutics aimed at treating cancer and other under-addressed diseases.
Additional Information
Based in Cambridge, Massachusetts, Syros is dedicated to expanding treatment options for patients and is positioned in the biotechnology sector, which is crucial for addressing healthcare challenges with its cutting-edge scientific research and development.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
68
CEO
Mr. Gerald E. Quirk Esq., J.D.
Country
United States
IPO Year
2016
Website
www.syros.comSyros Pharmaceuticals Inc. (SYRS) Latest News & Analysis
Latest News
Quick Summary
Syros Pharmaceuticals (NASDAQ: SYRS) announced plans for voluntary delisting from Nasdaq and deregistration of its common stock, ending its reporting obligations under the Securities Exchange Act.
Why It Matters
Syros Pharmaceuticals' decision to delist and deregister may signal financial distress, reduced visibility, and liquidity risks, potentially impacting shareholder value and market confidence.
Source: Business Wire
Market Sentiment:
Neutral
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
1 year ago
Quick Summary
Syros Pharmaceuticals' SELECT-MDS-1 Phase 3 trial for tamibarotene failed to meet its primary endpoint of complete response rate, according to a recent announcement.
Why It Matters
Syros Pharmaceuticals' failure to meet trial endpoints for tamibarotene can lead to decreased investor confidence, potential stock decline, and concerns over future product viability.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
SYRS stock declines significantly after its late-stage cancer study fails to meet primary endpoints, resulting in the study's termination.
Why It Matters
SYRS stock decline signals reduced confidence in its lead drug, impacting future revenue prospects and overall company valuation, raising concerns for potential investors.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Syros Pharmaceuticals' SELECT-MDS-1 Phase 3 trial of tamibarotene with azacitidine in HR-MDS patients failed to meet its primary endpoint of complete response rate.
Why It Matters
Failure to meet primary endpoints in a Phase 3 trial can lead to decreased stock value and investor confidence, impacting future funding and development opportunities for Syros Pharmaceuticals.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The Schall Law Firm is investigating Syros Pharmaceuticals (NASDAQ:SYRS) for potential securities law violations, including false statements and undisclosed information affecting investors.
Why It Matters
The investigation into Syros Pharmaceuticals for potential securities law violations may lead to legal repercussions, impacting stock value and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
The Schall Law Firm is investigating Syros Pharmaceuticals (NASDAQ:SYRS) for potential securities law violations, including possible misleading statements affecting investors.
Why It Matters
The investigation into Syros Pharmaceuticals for potential securities law violations may signal legal risks and financial repercussions, impacting investor confidence and stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About SYRS Stock
What is Syros Pharmaceuticals Inc.'s (SYRS) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Syros Pharmaceuticals Inc. (SYRS) has a median price target of $5.50. The highest price target is $20.00 and the lowest is $4.00.
Is SYRS stock a good investment in 2026?
According to current analyst ratings, SYRS has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.03. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SYRS stock?
Wall Street analysts predict SYRS stock could reach $5.50 in the next 12 months. This represents a 21,900.0% increase from the current price of $0.03. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Syros Pharmaceuticals Inc.'s business model?
Syros Pharmaceuticals utilizes its proprietary platform to discover and develop medicines by targeting gene regulatory regions. The company focuses on precision medicine, generating revenue through the advancement of innovative therapeutics aimed at treating cancer and other under-addressed diseases.
What is the highest forecasted price for SYRS Syros Pharmaceuticals Inc.?
The highest price target for SYRS is $20.00 from Edward Tenthoff at Piper Sandler, which represents a 79,900.0% increase from the current price of $0.03.
What is the lowest forecasted price for SYRS Syros Pharmaceuticals Inc.?
The lowest price target for SYRS is $4.00 from Jason Butler at JMP Securities, which represents a 15,900.0% increase from the current price of $0.03.
What is the overall SYRS consensus from analysts for Syros Pharmaceuticals Inc.?
The overall analyst consensus for SYRS is neutral. Out of 10 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $5.50.
How accurate are SYRS stock price projections?
Stock price projections, including those for Syros Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 3:21 PM UTC